Claims for Patent: 6,897,040

Summary for Patent: 6,897,040

Title:	Methods and host cells for improved cell culture
Abstract:	The invention provides improved methods of recombinant protein production in cell culture. More specifically, the invention relates to the modulation of the IGF-1 signaling pathway in cells so as to improve production characteristics.
Inventor(s):	Morris; Arvia E. (Seattle, WA), Reddy; Pranhitha (Seattle, WA)
Assignee:	Immunex Corporation (Seattle, WA)
Application Number:	10/109,971
Patent Claims:	1. An eukaryotic host cell genetically engineered to express a gene for a protein of interest, wherein the protein of interest is expressed as an extracellular product, and wherein the eukaryotic cell has been genetically engineered to also express a glut5 gene. 2. The host cell of claim 1 wherein the host cell is genetically engineered to express a second IGF-1-signaling pathway gene selected from the group consisting of a glut1 gene, an ERK1 gene, an ERK2 gene, a JNK gene, a 14-3-3 protein gene, an IRS gene, and a PI3 kinase gene. 3. The host cell of claim 2 wherein the glut5 gene is expressed under control of a heterologous regulatory element. 4. The host cell of claim 3, wherein the heterologous regulatory element is a viral promoter. 5. The host cell of claim 4, wherein the viral promoter is selected from the group consisting of a CMV promoter, an SV40 promoter, an RSV promoter and an adenoviral promoter. 6. The host cell of claim 1, wherein the protein of interest is selected from the group consisting of a soluble TNF receptor, a soluble IL-4 receptor, a soluble IL-1 type II receptor, a soluble Flt3 ligand, a soluble CD40 ligand, CD39, CD30, CD27, a TEK/Ork, IL-15, a soluble IL-15 receptor, Ox 40, GM-CSF, RANKL, RANK, TRAIL, a soluble TRAIL receptor, tissue plasminogen activator, Factor VIII, Factor IX, apolipoprotein E, apolipoprotein A-I, an IL-2 receptor, an IL-2 antagonist, alpha-1 antitrypsin, calcitonin, growth hormone, insulin, insulinotropin, insulin-like growth factors, parathyroid hormone, interferons, superoxide dismutase, glucagon, an erythropoeitin, an antibody, glucocerebrosidase, an Fc-fusion protein, a globin, a nerve growth factor, an interleukin, and a colony stimulating factor. 7. The host cell of claim 1, wherein the host cell is further genetically engineered to express a first selectable marker. 8. The host cell of claim 7, wherein the gene encoding the selectable marker is adjacent to the glut5 gene. 9. The host cell of claim 1, wherein the host cell is a mammalian cell. 10. The host cell of claim 9, wherein the host cell is selected from the group consisting of CHO, VERO, BHK, HeLa, CV1, MDCK, 293, 3T3, myeloma, PC12 and WI38 cells. 11. The host cell of claim 1, wherein the host cell is adapted to grow in serum-free medium. 12. The host cell of claim 11, wherein the host cell is a CHO. 13. A method of producing a protein of interest, the method comprising culturing the eukaryotic host cell of claim 1 under conditions such that the protein of interest is expressed. 14. The method of claim 13, wherein the host cell is genetically engineered to express a second IGF-1-signaling pathway gene selected from the group consisting of a glut1 gene, an ERK1 gene, an ERK2 gene, a JNK gene, a 14-3-3 protein gene, an IRS-1 gene, and a PI3 kinase gene. 15. The method of claim 13, further comprising collecting the protein of interest. 16. The method of claim 13, wherein the IGF-1-signaling pathway gene is expressed under control of a heterologous regulatory element. 17. The method of claim 16, wherein the heterologous regulatory element is a viral promoter. 18. The method of claim 17, wherein the viral promoter is selected from the group consisting of a CMV promoter, an SV40 promoter, an RSV promoter and an adenoviral promoter. 19. The method of claim 13, wherein the protein of interest is selected from the group consisting of a soluble TNF receptor, a soluble IL-4 receptor, a soluble IL-1 type II receptor, a soluble Flt3 ligand, a soluble CD40 ligand, CD39, CD30, CD27, a TEK/Ork, IL-15, a soluble IL-15 receptor, Ox 40, GM-CSF, RANKL, RANK, TRAIL, a soluble TRAIL receptor, tissue plasminogen activator, Factor VIII, Factor IX, apolipoprotein E, apolipoprotein A-I, an IL-2 receptor, an IL-2 antagonist, alpha-1 antitrypsin, calcitonin, growth hormone, insulin, insulinotropin, insulin-like growth factors, parathyroid hormone, interferons, superoxide dismutase, glucagon, an erythropoeitin, an antibody, glucocerebrosidase, an Fc-fusion protein, a globin, a nerve growth factor, an interleukin, and a colony stimulating factor. 20. The method of claim 13, wherein the host cell is further genetically engineered to express a first selectable marker. 21. The method of claim 20, wherein the gene encoding the selectable marker is adjacent to the glut5 gene. 22. The method of claim 13, wherein the host cell is a mammalian cell. 23. The method of claim 22, wherein the host cell is selected from the group consisting of CHO, VERO, BHK, HeLa, CV1, MDCK, 293, 3T3, myeloma, PC12 and WI38 cells. 24. The method of claim 13, wherein the host cell is cultured in serum-free medium. 25. The method of claim 24, wherein the medium is growth-factor free. 26. The method of claim 24, wherein the medium is protein-free. 27. The method of claim 26, wherein the medium is peptone-free. 28. The method of claim 13, wherein the host cell is a CHO cell. 29. A method of producing a mammalian cell line capable of growth in serum-free medium, the method comprising exposing cells that have been genetically engineered to overexpress a glut5 gene to serum-free medium, and isolating a cell line that grows in serum-free medium. 30. The method of claim 29, further comprising exposing the cells to peptone-free medium, and isolating a cell line that grows in peptone-free medium. 31. The method of claim 29, further comprising exposing the cells to protein-free medium, and isolating a cell line that grows in protein-free medium. 32. A method of producing an eukaryotic cell for production of a protein of interest, the method comprising genetically engineering an eukaryotic cell to express a protein of interest as an extracellular product, wherein the eukaryotic cell has been genetically engineered to also express a glut5 gene.

Details for Patent 6,897,040

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2019-08-25